The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease

E. S. Molho; S. A. Factor; W. J. Weiner; J. R. Sanchez-Ramos; C. Singer; L. Shulman; D. Brown; C. Sheldon

The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease

E. S. Molho, S. A. Factor, W. J. Weiner, J. R. Sanchez-Ramos, C. Singer, L. Shulman, D. Brown, C. Sheldon

Research output: Contribution to journal › Article › peer-review

Abstract

We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydrochloride], as adjunctive therapy in patients with advanced Parkinson's disease (PD). Twenty-four PD patients with motor fluctuations were treated in an 11 week prospective, single-blind parallel-group, placebo-controlled trial. The pramipexole treated group experienced a significant improvement in 'off' time functioning as measured by the activities of daily living portion of the United Parkinson's Disease Rating Scale. In addition, the active treatment group was able to reduce total levodopa dose by 30% (p < 0.05). Pramipexole was well tolerated and the side effects reported were typical of other dopamine agonists. We conclude that pramipexole has antiparkinsonian effects which make it potentially useful in the treatment of motor fluctuations in PD.

Original language	English (US)
Pages (from-to)	225-230
Number of pages	6
Journal	Journal of Neural Transmission, Supplement
Issue number	45
State	Published - Dec 11 1995
Externally published	Yes

ASJC Scopus subject areas

Neurology
Clinical Neurology
Psychiatry and Mental health
Biological Psychiatry

Fingerprint Dive into the research topics of 'The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease'. Together they form a unique fingerprint.

Cite this

@article{6c8754b0b4bf458f844155ac79200314,

title = "The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease",

abstract = "We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydrochloride], as adjunctive therapy in patients with advanced Parkinson's disease (PD). Twenty-four PD patients with motor fluctuations were treated in an 11 week prospective, single-blind parallel-group, placebo-controlled trial. The pramipexole treated group experienced a significant improvement in 'off' time functioning as measured by the activities of daily living portion of the United Parkinson's Disease Rating Scale. In addition, the active treatment group was able to reduce total levodopa dose by 30% (p < 0.05). Pramipexole was well tolerated and the side effects reported were typical of other dopamine agonists. We conclude that pramipexole has antiparkinsonian effects which make it potentially useful in the treatment of motor fluctuations in PD.",

author = "Molho, {E. S.} and Factor, {S. A.} and Weiner, {W. J.} and Sanchez-Ramos, {J. R.} and C. Singer and L. Shulman and D. Brown and C. Sheldon",

year = "1995",

month = dec,

day = "11",

language = "English (US)",

pages = "225--230",

journal = "Journal of Neural Transmission, Supplement",

issn = "0303-6995",

publisher = "Springer Wien",

number = "45",

}

TY - JOUR

T1 - The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease

AU - Molho, E. S.

AU - Factor, S. A.

AU - Weiner, W. J.

AU - Sanchez-Ramos, J. R.

AU - Singer, C.

AU - Shulman, L.

AU - Brown, D.

AU - Sheldon, C.

PY - 1995/12/11

Y1 - 1995/12/11

N2 - We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydrochloride], as adjunctive therapy in patients with advanced Parkinson's disease (PD). Twenty-four PD patients with motor fluctuations were treated in an 11 week prospective, single-blind parallel-group, placebo-controlled trial. The pramipexole treated group experienced a significant improvement in 'off' time functioning as measured by the activities of daily living portion of the United Parkinson's Disease Rating Scale. In addition, the active treatment group was able to reduce total levodopa dose by 30% (p < 0.05). Pramipexole was well tolerated and the side effects reported were typical of other dopamine agonists. We conclude that pramipexole has antiparkinsonian effects which make it potentially useful in the treatment of motor fluctuations in PD.

AB - We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydrochloride], as adjunctive therapy in patients with advanced Parkinson's disease (PD). Twenty-four PD patients with motor fluctuations were treated in an 11 week prospective, single-blind parallel-group, placebo-controlled trial. The pramipexole treated group experienced a significant improvement in 'off' time functioning as measured by the activities of daily living portion of the United Parkinson's Disease Rating Scale. In addition, the active treatment group was able to reduce total levodopa dose by 30% (p < 0.05). Pramipexole was well tolerated and the side effects reported were typical of other dopamine agonists. We conclude that pramipexole has antiparkinsonian effects which make it potentially useful in the treatment of motor fluctuations in PD.

UR - http://www.scopus.com/inward/record.url?scp=0028971708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028971708&partnerID=8YFLogxK

M3 - Article

C2 - 8748629

AN - SCOPUS:0028971708

SP - 225

EP - 230

JO - Journal of Neural Transmission, Supplement

JF - Journal of Neural Transmission, Supplement

SN - 0303-6995

IS - 45

ER -

The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease

Abstract

ASJC Scopus subject areas

Other files and links

Cite this